01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – New Contract win for Open Orphan’s Breda office July 14, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a new contract win of c. €900,000 with an existing customer for clinical trial management by our Breda, Netherlands office. Cathal Friel, Executive Chairman of Open Orphan, said: “This new contract win demonstrates the ongoing and continued success of our Breda office which continues to sign multiple…

Continue reading

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its acquisition by Open Orphan Plc on the 17 January 2020.   Operational Highlights: ·    Completed the acquisition of hVIVO…

Continue reading

Open Orphan #ORPH – Option to Acquire CHIMagents Limited July 15, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce it has signed an option to acquire (the “Option”) CHIMagents Limited (“CHIMagents”) for a nominal sum. CHIMagents was recently established to assist in the design, manufacture and testing of challenge agents for use in challenge studies. CHIMagents was established by an experienced…

Continue reading